14. Serial evaluation of the effect of hormonal therapy on urinary function in men receiving 3D conformai radiation therapy for prostate cancer

Research output: Contribution to journalArticle

Abstract

Purpose: We evaluated the effect of 3D conformai radiation therapy (3DCRT) on urinary function (UF) in prostate cancer patients whose urinary function scores were known prior to treatment in two groups of patients: those who had received hormonal therapy (HT) prior to radiation treatment, and those who did not receive any HT. Materials and Methods: Between September 1996 and November 2000, 86 patients received 3DCRT for prostate cancer and had UF data available both before and after treatment. All data was collected serially using a AUA/I-PSS Urological Symptom Survey, a validated, self-administered, validated instrument. Hormonal therapy consisted of 3 to 6 months of an LH RH agonist with or without an anti-androgen. The Wilcoxon rank sum tests as well as linear regression analysis were used to determine statistical significance. Results: Before 3-D CRT (median dose = 70 Gy), 30 patients (3 men excluded because of HT lasting 6 months.) that had received hormonal therapy had a significantly higher baseline AUA score than the 53 men receiving 3D CRT alone (10.7 vs.6.4, pO.Ol). At first follow-up and lyear follow-up visits, there were no significant declines in AUA scores. In comparing the relative change in scores between the two groups, we carried out linear regression analysis controlling for differing follow-up intervals. After adjusting for baseline score, volume, and dose, the slope of scores was not significantly different (-0.38 and -0.39 |P = 0.9] for 3D CRT alone group and HT group, respectively). Conclusion: Prior to any treatment, men receiving HT with 3D CRT tended to have significantly higher AUA symptom scores at baseline. After controlling for confounding factors, HT did not appear to influence post-treatment urinary function as compared to men receiving 3D CRT alone. These data suggest that HT does not contribute to additional urinary toxicity.

Original languageEnglish (US)
Pages (from-to)488
Number of pages1
JournalCancer Journal
Volume9
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Therapeutics
Nonparametric Statistics
Linear Models
Regression Analysis
Group Psychotherapy
Gonadotropin-Releasing Hormone
Androgens
Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{09345f63300046c9ae9953e9d76d7005,
title = "14. Serial evaluation of the effect of hormonal therapy on urinary function in men receiving 3D conformai radiation therapy for prostate cancer",
abstract = "Purpose: We evaluated the effect of 3D conformai radiation therapy (3DCRT) on urinary function (UF) in prostate cancer patients whose urinary function scores were known prior to treatment in two groups of patients: those who had received hormonal therapy (HT) prior to radiation treatment, and those who did not receive any HT. Materials and Methods: Between September 1996 and November 2000, 86 patients received 3DCRT for prostate cancer and had UF data available both before and after treatment. All data was collected serially using a AUA/I-PSS Urological Symptom Survey, a validated, self-administered, validated instrument. Hormonal therapy consisted of 3 to 6 months of an LH RH agonist with or without an anti-androgen. The Wilcoxon rank sum tests as well as linear regression analysis were used to determine statistical significance. Results: Before 3-D CRT (median dose = 70 Gy), 30 patients (3 men excluded because of HT lasting 6 months.) that had received hormonal therapy had a significantly higher baseline AUA score than the 53 men receiving 3D CRT alone (10.7 vs.6.4, pO.Ol). At first follow-up and lyear follow-up visits, there were no significant declines in AUA scores. In comparing the relative change in scores between the two groups, we carried out linear regression analysis controlling for differing follow-up intervals. After adjusting for baseline score, volume, and dose, the slope of scores was not significantly different (-0.38 and -0.39 |P = 0.9] for 3D CRT alone group and HT group, respectively). Conclusion: Prior to any treatment, men receiving HT with 3D CRT tended to have significantly higher AUA symptom scores at baseline. After controlling for confounding factors, HT did not appear to influence post-treatment urinary function as compared to men receiving 3D CRT alone. These data suggest that HT does not contribute to additional urinary toxicity.",
author = "Valicenti, {Richard K}",
year = "1996",
language = "English (US)",
volume = "9",
pages = "488",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - 14. Serial evaluation of the effect of hormonal therapy on urinary function in men receiving 3D conformai radiation therapy for prostate cancer

AU - Valicenti, Richard K

PY - 1996

Y1 - 1996

N2 - Purpose: We evaluated the effect of 3D conformai radiation therapy (3DCRT) on urinary function (UF) in prostate cancer patients whose urinary function scores were known prior to treatment in two groups of patients: those who had received hormonal therapy (HT) prior to radiation treatment, and those who did not receive any HT. Materials and Methods: Between September 1996 and November 2000, 86 patients received 3DCRT for prostate cancer and had UF data available both before and after treatment. All data was collected serially using a AUA/I-PSS Urological Symptom Survey, a validated, self-administered, validated instrument. Hormonal therapy consisted of 3 to 6 months of an LH RH agonist with or without an anti-androgen. The Wilcoxon rank sum tests as well as linear regression analysis were used to determine statistical significance. Results: Before 3-D CRT (median dose = 70 Gy), 30 patients (3 men excluded because of HT lasting 6 months.) that had received hormonal therapy had a significantly higher baseline AUA score than the 53 men receiving 3D CRT alone (10.7 vs.6.4, pO.Ol). At first follow-up and lyear follow-up visits, there were no significant declines in AUA scores. In comparing the relative change in scores between the two groups, we carried out linear regression analysis controlling for differing follow-up intervals. After adjusting for baseline score, volume, and dose, the slope of scores was not significantly different (-0.38 and -0.39 |P = 0.9] for 3D CRT alone group and HT group, respectively). Conclusion: Prior to any treatment, men receiving HT with 3D CRT tended to have significantly higher AUA symptom scores at baseline. After controlling for confounding factors, HT did not appear to influence post-treatment urinary function as compared to men receiving 3D CRT alone. These data suggest that HT does not contribute to additional urinary toxicity.

AB - Purpose: We evaluated the effect of 3D conformai radiation therapy (3DCRT) on urinary function (UF) in prostate cancer patients whose urinary function scores were known prior to treatment in two groups of patients: those who had received hormonal therapy (HT) prior to radiation treatment, and those who did not receive any HT. Materials and Methods: Between September 1996 and November 2000, 86 patients received 3DCRT for prostate cancer and had UF data available both before and after treatment. All data was collected serially using a AUA/I-PSS Urological Symptom Survey, a validated, self-administered, validated instrument. Hormonal therapy consisted of 3 to 6 months of an LH RH agonist with or without an anti-androgen. The Wilcoxon rank sum tests as well as linear regression analysis were used to determine statistical significance. Results: Before 3-D CRT (median dose = 70 Gy), 30 patients (3 men excluded because of HT lasting 6 months.) that had received hormonal therapy had a significantly higher baseline AUA score than the 53 men receiving 3D CRT alone (10.7 vs.6.4, pO.Ol). At first follow-up and lyear follow-up visits, there were no significant declines in AUA scores. In comparing the relative change in scores between the two groups, we carried out linear regression analysis controlling for differing follow-up intervals. After adjusting for baseline score, volume, and dose, the slope of scores was not significantly different (-0.38 and -0.39 |P = 0.9] for 3D CRT alone group and HT group, respectively). Conclusion: Prior to any treatment, men receiving HT with 3D CRT tended to have significantly higher AUA symptom scores at baseline. After controlling for confounding factors, HT did not appear to influence post-treatment urinary function as compared to men receiving 3D CRT alone. These data suggest that HT does not contribute to additional urinary toxicity.

UR - http://www.scopus.com/inward/record.url?scp=33749566585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749566585&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749566585

VL - 9

SP - 488

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 6

ER -